DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants

Phase 1

Completed

Conditions: Drug Interactions

Interventions: Drug: BAY1902607
Drug: Itraconazole

First Posted Date: 2018-12-31

Last Posted Date: 2019-05-29

Lead Sponsor: Bayer

Target Recruit Count: 14

Registration Number: NCT03789890

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

Rogaratinib (BAY1163877) in Chinese Patients

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Rogaratinib (BAY1163877)

First Posted Date: 2018-12-27

Last Posted Date: 2021-03-29

Lead Sponsor: Bayer

Target Recruit Count: 1

Registration Number: NCT03788603

Locations: 🇨🇳
Beijing Hospital, Beijing, China

End-stage Renal Disease (ESRD) Pilot Study

Phase 1

Completed

Conditions: Renal Dialysis

Interventions: Drug: BAY1213790
Drug: 0.9% sodium chloride solution

First Posted Date: 2018-12-26

Last Posted Date: 2022-03-16

Lead Sponsor: Bayer

Target Recruit Count: 55

Registration Number: NCT03787368

Locations: 🇪🇸
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
🇧🇪
CHU de Charleroi Hôpital civil, Lodelinsart, Hainaut, Belgium
🇺🇸
California Institute of Renal Research - Chula Vista, Chula Vista, California, United States

and more 12 locations

Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

Completed

Conditions: Chagas' Disease

Interventions: Drug: Lampit (Nifurtimox, BAYA2502)

First Posted Date: 2018-12-21

Last Posted Date: 2021-04-08

Lead Sponsor: Bayer

Target Recruit Count: 3000

Registration Number: NCT03784391

Locations: 🇦🇷
Many locations, Multiple Locations, Argentina

A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein

Phase 1

Completed

Conditions: Biological Availability

Interventions: Drug: BAY1817080 - Formulation B
Drug: BAY1817080 - Formulation A
Drug: [13C715N]-BAY 181708 stable isotope label (SIL)

First Posted Date: 2018-12-12

Last Posted Date: 2019-08-19

Lead Sponsor: Bayer

Target Recruit Count: 30

Registration Number: NCT03773068

Locations: 🇳🇱
PRAHealthSciences, Groningen, Netherlands

Study to Find Out How Symptoms Severity Changes During the Standard Course of Treatment With the Cream Relief Pro and Suppositories Relief Pro (Active Ingredients Are Fluocortolone + Lidocaine) in Patients Suffering From Twisted and Bulging Veins in the Rectal Area (Acute Hemorrhoids)

Completed

Conditions: Acute Hemorrhoids

Interventions: Drug: Relief Pro cream
Drug: Relief Pro rectal suppositories

First Posted Date: 2018-11-28

Last Posted Date: 2020-10-23

Lead Sponsor: Bayer

Target Recruit Count: 1000

Registration Number: NCT03757078

Locations: 🇷🇺
State Scientific Center of Coloproctology, Moscow, Russian Federation

This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Phase 1

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: BAY1237592

First Posted Date: 2018-11-27

Last Posted Date: 2025-05-07

Lead Sponsor: Bayer

Target Recruit Count: 38

Registration Number: NCT03754660

Locations: 🇨🇿
Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia
🇦🇹
Medizinische Universität Graz, Graz, Austria
🇨🇿
Institut Klinicke a Experimentalni Mediciny, Praha 4, Czechia

and more 5 locations

Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs

Completed

Conditions: Intrauterine Devices

Interventions: Device: Intrauterine device

First Posted Date: 2018-11-27

Last Posted Date: 2020-12-04

Lead Sponsor: Bayer

Target Recruit Count: 326658

Registration Number: NCT03754556

Locations: 🇺🇸
Kaiser Permanente Northern California, Oakland, California, United States
🇺🇸
Kaiser Permanente Southern California, Pasadena, California, United States
🇺🇸
Regenstrief Institute, Indianapolis, Indiana, United States

and more 1 locations

A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment

Completed

Conditions: Menorrhagia

Interventions: Drug: Chronic hormonal treatment

First Posted Date: 2018-11-23

Last Posted Date: 2024-10-18

Lead Sponsor: Bayer

Target Recruit Count: 422

Registration Number: NCT03751800

Locations: 🇪🇸
Many locations, Many locations, Spain

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation

Completed

Conditions: Non-valvular Atrial Fibrillation (NVAF)

Interventions: Drug: Rivaroxaban(Xarelto,BAY 59-7939)

First Posted Date: 2018-11-19

Last Posted Date: 2022-12-08

Lead Sponsor: Bayer

Target Recruit Count: 924

Registration Number: NCT03746301

Locations: 🇰🇷
Many locations, Multiple Locations, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy